Using the representational difference analysis (RDA) technique on pooled mRNA of five primary lung adenocarcinomas and their corresponding non-neoplastic lung tissues, we identified six genes that were putatively overexpressed in this type of lung cancer. Five corresponded to previously isolated genes, while one (Lc19) matched with the sequence of an unannotated EST. Real-time RT -PCR analyses of expression levels in a panel of 34 paired primary non-small cell lung cancer (NSCLC) and corresponding grossly normal appearing lung tissues confirmed the common overexpression of these genes in non-small cell lung cancer. Among these genes, overexpression of Lc19, hyaluronan binding protein 2 (HABP2) and crystalline-mu appeared more specific to adenocarcinoma, whereas ceruloplasmin, integrin a-11 and collagen type XI alpha 1 were overexpressed at high frequency among both adenocarcinoma and squamous cell carcinoma. These genes represent novel candidate tumor biomarker genes for NSCLC and its histological subtypes.
Introduction
Lung cancer is the second most common cancer among men and women in North America, but has the highest cancer-related mortality in both sexes (Greenlee et al., 2001) . Despite continuing improvement in response rate to successive generations of chemotherapeutic agents, the mortality rate for lung cancer patients has not significantly changed during the last two decades. Tumor stage remains the most important determinant for survival (Mountain, 1997) . Since approximately 70% of lung cancer patients are discovered with advanced stage disease, early detection is generally recognized as the most effective strategy to reduce mortality. However, even among early stage (I and II) patients who are treated by complete surgical resection, the recurrence and mortality rates remain at 30 -50%. An ability to detect post-operative residual tumor cells, occult metastases or early tumor recurrence potentially may improve survival by early aggressive adjuvant therapy. In situations involving early detection of primary, minimal residual or recurrent disease, the availability of cancer cell specific biomarkers is essential for the development of effective screening modalities.
Several strategies have been employed to identify potential lung cancer biomarker genes or proteins. These include the raising of mouse monoclonal antibodies against extracts of human lung cancer cell lines (Tockman et al., 1988) and identification of genetic changes that commonly occur in lung cancer (Rom et al., 2000) . Biomarkers have been used to assay for circulating tumor cell derived antigens (Hirota et al., 1985; Lubin et al., 1995) , and to detect tumor specific genetic changes such as loss of heterozygosity for the FHIT gene locus (Sozzi et al., 1999) , Ki-ras and p53 gene mutations (Mao et al., 1994; Kersting et al., 2000) , genomic instability (Liloglou et al., 2001 ) and promoter demethylation of certain genes that are commonly inactivated in lung cancer cells (Palmisano et al., 2000; Kersting et al., 2000) . The appropriate use of lung cancer specific biomarkers as targets for imaging techniques may also improve the accuracy of detection of early or occult residual disease. Recent advances in high throughput genome wide expression profiling techniques provide unprecedented opportunities to identify many additional cancer cell biomarkers.
We used the Representational Difference Analysis (RDA) technique to isolate genes that are differentially expressed in lung adenocarcinoma as compared to the normal lung parenchyma (Lisitsyn et al., 1993; Hubank and Schatz, 1994) using pooled RNA samples of paired tumor and normal tissues obtained from five patients. Tissues were harvested with informed consent according to a protocol approved by the Research Ethics Board and Human Tissue Committee of the University Health Network. Tissues were obtained within 15 -30 min after resection, snap-frozen and stored in liquid nitrogen until use. Tumor cells constituted approxi-mately 50 -80% of the tumor tissues and we restricted the samples to well or moderately differentiated adenocarcinoma with wild type ras genotype. RDA is a PCR-based technique that is conceptually similar to other subtractive hybridization methods to remove common sequences from the tester representational cDNA population by hybridizing to excess amount of the corresponding driver cDNA population. This results in enrichment of the sequences unique to the tester. Pooled samples were used to overcome the problem of normal and tumor tissue heterogeneity. Pooling of samples should not decrease the sensitivity, since RDA is designed to identify differentially expressed genes (in our case between normal and tumor tissues), regardless of the absolute amount of RNA transcript expressed. The use of pooled samples added the advantage of requiring less RNA from each sample, which is an important consideration in view of the limited amount of tissue available.
Three successive rounds of subtraction-amplification using pooled RNA from primary lung adenocarcinoma vs corresponding grossly normal appearing lung parenchyma with successive tester to driver ratios of 1 : 100, 1 : 800 and 1 : 400 000 yielded differential products (DPs) with increasingly defined bands (data not shown). The sequencing of clones from the third cycle product (DP3) and limited RT -PCR screening revealed five genes that are consistently overexpressed in tumors as compared to the corresponding normal lung tissue. These are: Lc19 (novel partial mRNA corresponding to IMAGE clone 3938286), hyaluronan binding protein 2 (HABP2), crystalline-mu (CRYM), ceruloplasmin (CP) and integrin alpha-11 (ITGA11).
To identify additional candidate genes, we differentially hybridized DP3 against the driver (normal lung tissue) amplicon library using a human 19.2 K cDNA microarray containing 19 200 known and EST sequences (Wigle et al., 2002) . This strategy has previously been reported to identify additional differentially expressed clones in subtracted libraries of RDA (Welford et al., 1998) . Nine clones on the microarray showed greater than 15-fold signal levels in DP3 compared to the normal lung tissue amplicon; these included ceruloplasmin (CP) and crystalline-mu (CRYM). Among the remaining seven genes, only collagen type XI alpha 1 (COL11A1) showed consistent overexpression in the five original tumor samples compared to their corresponding non-neoplastic lungs. HABP2 and ITGA11 were not represented on the microarray.
To determine the frequency of overexpression of these six genes in lung cancer, we used the real-time quantitative RT -PCR with the ABI PRISM 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems, Foster City, CA, USA) in a panel of 34 primary NSCLC and their corresponding non-neoplastic lung tissues (Table 1 ). All PCR products demonstrated a single band by gel electrophoresis. The relative abundance of a transcript was represented by the threshold cycle of amplification (C T ), which is inversely correlated to the amount of target RNA/first strand cDNA being amplified. To normalize for equal amounts of the latter, we also assayed the transcript levels of putative housekeeping genes glyceraldehydes 6-phosphate dehydrogenase (GAPDH) and 18s ribosomal RNA. As shown in Table 2 , amplification using 18S primers consistently yielded similar C T levels among all types of tissue, whereas on average GAPDH was expressed 3 -6-fold more abundantly in cancerous than in non-neoplastic lung tissue of these patients. Table 2 also shows the mean C T of various genes in RNA samples isolated from 19 primary ADC, 15 SQCC and 34 corresponding non-involved lung parenchyma tissues from these lung cancer patients. Expression heterogeneity among the non-neoplastic lung tissues was noted for all genes, with approximately 10 -25% of samples demonstrating expression values greater than the upper 95% CI of the mean/ average expression level (Nav, average of normal) of all 34 non-neoplastic lung tissues studied. Outlier cases for each gene were not restricted to certain samples, and histological examinations of the hematoxylin eosin stained sections of these samples confirmed their nonneoplastic nature. These samples demonstrated varying degrees of emphysematous changes, fibrosis and alveolar macrophage accumulation, consistent with most of them belonging to long-term smoker patients.
The mean expression levels of the six candidate biomarker genes in primary ADC ranged from 6.1-fold (CRYM) to 124-fold (Lc19) greater than that in nonneoplastic lung tissue (Table 2 and Figure 1 ). ADC samples that showed expression values higher than the 95% CI of Nav ranged from approximately 50 to 90%. Genes most commonly overexpressed included CP, ITGA and COL11A1. In contrast to ADC, SQCC expressed significantly lower levels of Lc19, HABP2 and CRYM than normal lung tissue, but they also commonly overexpressed CP, ITGA11 and COL11A1. COL11A1 demonstrated even greater overexpression levels in SQCC than in ADC. Overall the findings demonstrate that Lc19, HABP2 and CRYM may represent candidate biomarker genes for lung ADC, while CP, ITGA11 and COL11A1 may serve as markers for both ADC and SQCC. It is worth noting that fourfold overexpression of at least one of these genes was found in all ADC cases (Figure 2b) , and cooverexpression of three genes could distinguish tumors from non-neoplastic lung tissue in approximately threequarters of the cases (Table 3) .
To assess the potential usefulness of these candidate genes as lung cancer tumor markers, we studied their relative expression levels in grossly normal appearing tissue from other organs that had been surgically resected for various medical diagnoses. The variety of tissues studied was limited by their availability but included liver, duodenum, colonic mucosa (two), spleen, pancreas, parotid gland, kidney, thymus (two), bladder, ovary and testicle. Except for COL11A1, the mean C T in these normal tissues was uniformly higher than that in normal lung tissue, indicating low or absent expression (Table 2 and Figure 2c ). Occasional organs demonstrated high expression of one or more of these genes, for example, liver for HABP2 and CP, and parotid gland for COL11A1.
Applying the representational differences analysis (RDA) previously used to isolate unique gene sequences between two DNA or RNA samples (Lisitsyn et al., 1993; Hubank and Schatz, 1994; Braun et al., 1995) , we have identified six genes commonly overexpressed in primary NSCLC as compared to their corresponding normal lung tissue. None of these have previously been reported or considered to play significant roles in lung cancer. The unknown gene Lc19 has only been partially cloned in EST sequences, but the putative protein product from human genomic sequence shows homology to the glycosidase superfamily proteins. Further screening of the expression of these six genes among 34 paired NSCLC and corresponding normal lung tissues has established the frequency and levels of their differential overexpression in primary lung adenocarcinoma. Three of them were also commonly overexpressed in lung SQCC. Therefore, these genes should be regarded as novel candidate biomarkers for detection.
Genes that are uniquely expressed or commonly overexpressed in lung cancer cells/tissues but that are rarely expressed in normal lung tissue may potentially serve as cancer cell markers in sputum and/or serum samples, or as targets for development of in vivo bioimaging reagents. Recently, several techniques have been applied to identify such candidate lung cancer biomarker genes, including serial analysis of gene expression or SAGE (Hibi et al., 1998) , differential display (Manda et al., 1999; Iwao et al., 2001; Hsu et al., 2001) , and subtractive hybridization (Schraml et al., 1994; Wang et al., 2000) . Most of these studies have used squamous cell carcinoma tissue or NSCLC cell lines as their study materials. Genes that have been The amount of RNA/RT product for each assay was 20 ng for 18 s and 100 ng for all other genes. c N/Nav refers to the ratio of expression level of each specimen relative to the mean (average) expression level of all non-neoplastic lung tissue (Nav).
d Number of specimens with expression level greater than the upper 95% CI of Nav. Comparative C T method was calculated as per manufacturer's instructions. To normalize the C T of target gene X for each sample, we calculate=C T (X)7C T (18s). We then calculate the mean DC T (X) for all normal lung specimens as DC T (X) Nav . The expression level of gene X in each sample (n) relative to the mean expression level in normal lung tissue was calculated as 2 DDC T (X)n , with DDC T (X)n=DC T (X)n7DC T (X) Nav . GAPDH, glyceraldehydes 6-phosphate dehydrogenase; HABP2, hyaluronan binding protein 2; CRYM: crystalline-mu; CP, ceruloplasmin; ITGA11, integrin alpha-11; COL11A1, collagen type XI, alpha-1 identified included PGP9.5, C20orf2, spr1, dihydrodiol dehydrogenase, IGF-beta2, PTHrP, ATM, aldose reductase homolog, ADH7, KOC and NMB. Recent reports on cDNA microarray analysis of NSCLC and normal lung tissue have suggested additional marker genes for various subtypes of lung cancer, but their differential expression status has not yet been validated (Garber et al., 2001; Bhattacharjee et al., 2001) . Our study was specifically aimed at isolating and identifying candidate cancer marker genes for lung ADC, and it was conceived in the context of the increasingly important roles that ADC is assuming in lung cancer (Thun et al., 1997; Wynder and Hoffmann, 1997) .
We chose RDA as our technology platform based on its putative specificity for isolating genes that are uniquely present in the tester RNA sample but not in the driver sample (Hubank and Schatz, 1994; Pastorian et al., 2000) . The technique allows the presence of contaminating driver tissue/cells in the tester sample. Interestingly, the highest level of expression of these genes tended to occur in one or more of the original tumors used as the starting material for the RDA. The results also showed that there is a significant heterogeneity in gene expression changes occurring in NSCLC and non-neoplastic lung tissues obtained from lung cancer resection specimens. We believe RDA represents a very powerful technique to narrow down the number of candidate biomarker genes for further validation studies.
Except for ceruloplasmin, very little is known about the biological and patho-physiological roles of the other five differentially expressed genes we identified. Lc19 corresponds to an EST originally sequenced from a small cell carcinoma cDNA library. Crystallin-mu (CRYM) was originally identified as a major lens structural protein in many species of Australian Figure 1 The level of gene expression for each sample (normal or tumor) relative to the average expression level of all non-neoplastic lung tissue (Nav). N-lung, non-neoplastic lung tissues; N-others, grossly normal appearing part of surgically resected organs other than lung marsupials. The human homologue is located on 16p13.11 -12.3 and it is expressed mainly in nerves, muscles and kidney (Chen et al., 1992) . Our findings that Lc19 and CRYM are overexpressed in a significant number of lung ADC suggest potentially novel roles for these genes in neoplasia.
The integrin-a11 (ITGA11) was initially isolated from a cDNA library of cultured human fetal myoblasts, and it encodes a protein of 1188 amino acids and contains a transmembrane region and 24-amino acid cytoplasmic tail (Velling et al., 1999; Lehnert et al., 1999) . The gene is located on chromosome 15q23. Expression of ITGA11 has been detected mainly in muscle-containing tissue, and our own analysis confirmed its low expression in predominantly epithelium-containing adult tissue. A recent study indicates that ITGA11 is a receptor for interstitial collagen I in mesenchymal derived cells, and may mediate cellular adhesion to collagen fibers and support cell migration on collagen I in response to (Tiger et al., 2001) . The latter suggests a potential role in tumor cell invasion.
Collagen type XI alpha 1 (COL11A1) is a minor fibril component of cartilage (Morris and Bachinger, 1988) . It is widely expressed in non-cartilaginous fetal tissue of chicken (Nah et al., 1992) . Our study indicates that a low level of COL11A1 is expressed in a wide variety of normal adult human tissues including lung, with the highest expression detected in parotid gland. Little is known about the function of COL11A1 aside from its demonstrated importance in regulating the assembly, organization and development of cartilage. Genomic mutations in the COL11A1 gene are the basis for Stickler and Marshall syndromes (Griffith et al., 1998; Richards et al., 1996) . Frequent and high level overexpression of COL11A1 in NSCLC, especially SQCC, indicates the importance of further investigations into the potential role for this gene/protein in lung carcinogenesis and tumor progression.
Both ceruloplasmin and hyaluronan binding protein 2 (HABP2) are components of plasma/serum protein. The HABP2 gene was isolated from a human liver cDNA library and encodes a 560 amino acid protein with significant homology to the hepatocyte growth factor activator. It demonstrates serine protease activity (Choi-Miura et al., 1996; Sumiya et al., 1997) . HABP2 contains a signal peptide, three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain. Northern blot analysis has demonstrated expression in human adult kidney, liver and pancreas, consistent with our own findings. Since other serine protease family members including tissue-type plasminogen activator and urokinase have been demonstrated to play important roles in invasion and metastasis, the biological significance of HABP2 overexpression in lung adenocarcinoma is worthy of further investigations. It also remains to be determined if levels of HABP2 in the serum/plasma of lung cancer patients are elevated, and if it may serve as a potential serum tumor marker for lung cancer patients.
The identification of ceruloplasmin as a common differentially overexpressed gene in lung cancer suggests a novel role of this protein in oncogenesis. It was known more than two decades ago that cancer patients often show substantial elevation in serum copper concentration and ceruloplasmin levels. Linder et al. (1981) reported that serum ceruloplasmin was significantly increased above normal in lung cancer patients prior to treatment, and the degree of elevation correlated with higher tumor TNM stage and poorer prognosis. High levels of ceruloplasmin have been shown to return gradually to normal post-surgery, may be detected before tumor recurrence, and may precede subsequent development of lung cancer. Prior reports have generally considered ceruloplasmin as an acute phase reactive protein, thus elevated levels in cancer patients were thought to represent non-specific physiological responses. Our findings for the first time indicate that elevated ceruloplasmin levels in cancer patients may originate from over-expression by cells in the tumor. Consistent with this, we have detected ceruloplasmin mRNA expression in several NSCLC cell lines (data not shown). It remains to be determined if overexpression of ceruloplasmin by the lung cancer cells would have a significant role in the biology of the tumor cells themselves. However, the usefulness of ceruloplasmin levels as a serum marker for early detection of lung cancer appears limited, since serum ceruloplasmin level has been shown to be elevated in patients with non-malignant lung disease including smokers, in women with both benign and malignant diseases, and in patients with various gastrointestinal cancers. It remains possible that sputum level of ceruloplasmin and HABP2 could be useful for such purposes.
In summary, we have used the RDA technique to isolate six novel candidate biomarker genes for NSCLC, some of which appear more specific for ADC than SQCC. We have also shown that almost all lung ADC overexpress at least one of these genes. The role of these genes in the biology and pathogenesis of lung cancer and their potential value as biomarkers for lung cancer cell detection during disease recurrence requires further investigation. The fact that several of these differentially overexpressed genes appear to have their functions mainly in the extracellular milieu or compartment also suggests that tumor stroma may contain critical gene products for the diagnosis and therapeutic targeting in lung cancer. 
